Collaborations & Alliances

Aduro Earns Merck Milestone

Initiates anti-CD27 Phase I trial in advanced solid tumors

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aduro Biotech, Inc. has earned a $3 million development milestone under its worldwide licensing agreement with Merck for the initiation of a Phase I trial of its anti-CD27 antibody. The Phase I trial will evaluate the safety and pharmacokinetics of the anti-CD27 antibody when administered alone and in combination with pembrolizumab in adults with advanced solid tumors. CD27 is a co-stimulatory receptor expressed on different immune cells, such as T-lymphocytes and NK (natural killer) cells. I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters